Bionomics Limited (NASDAQ:BNOX – Get Free Report) saw a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 165,600 shares, a decrease of 35.9% from the March 31st total of 258,400 shares. Based on an average trading volume of 155,700 shares, the short-interest ratio is currently 1.1 days.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Bionomics stock. Lynx1 Capital Management LP bought a new stake in shares of Bionomics Limited (NASDAQ:BNOX – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 815,512 shares of the company’s stock, valued at approximately $2,202,000. Bionomics comprises about 1.5% of Lynx1 Capital Management LP’s holdings, making the stock its 12th largest position. Lynx1 Capital Management LP owned about 9.99% of Bionomics at the end of the most recent quarter. 15.90% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Bionomics in a research note on Thursday, March 21st.
Bionomics Stock Performance
Shares of BNOX stock traded up $0.03 during mid-day trading on Friday, hitting $1.00. The company’s stock had a trading volume of 43,731 shares, compared to its average volume of 190,867. Bionomics has a 52 week low of $0.87 and a 52 week high of $6.41. The company’s fifty day simple moving average is $1.07 and its 200-day simple moving average is $1.55.
Bionomics Company Profile
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
See Also
- Five stocks we like better than Bionomics
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Stocks Leading the U.S. Agriculture Comeback
- Using the MarketBeat Stock Split Calculator
- How to Use Put Debit Spreads to Profit From Falling Stocks
- 3 Healthcare Dividend Stocks to Buy
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.
